Latest Regulatory Delays News

GBM Resources has partially completed its $8 million placement to Wise Walkers but faces delays in receiving the remaining funds due to Chinese foreign exchange controls. Shareholder approval for the balance is now pending.

Marvel Gold Limited has agreed to sell its Yanfolila Gold Project in Mali to Askiya Mineral Resources for up to US$1.94 million, marking a strategic shift to focus on its Tanzanian assets.

Minbos Resources has postponed the start of its Share Purchase Plan as it awaits a critical ASX decision on a waiver application, leaving the timetable uncertain.

Lunnon Metals reports significant high-grade gold assay results from the Lady Herial deposit, confirming promising mineralisation below and within the planned open pit. The company advances towards regulatory approvals and a final investment decision.

TPC Consolidated’s proposed acquisition by Wollar Holding Ltd hits a regulatory snag as FIRB approval misses the November 28 sunset deadline, casting uncertainty over the deal’s future.

Iris Cairns Property Pty Ltd has announced a delay in its takeover bid for Reef Casino Trust due to extended regulatory approval timelines, signaling a planned extension of the offer period beyond May 2026.

Reef Casino Trust has lodged a supplementary statement revealing delays in regulatory approvals that are likely to extend the takeover bid timeline by Iris Cairns Property. The board maintains its recommendation to accept the offer despite the uncertainty.

Reef Casino Trust’s takeover bid by Iris Cairns Property faces a regulatory hurdle as Queensland’s Office of Liquor and Gaming Regulation delays suitability investigations, pushing the offer period beyond March 2026.

Mayne Pharma’s acquisition by Cosette Pharmaceuticals faces a brief delay as FIRB extends its approval deadline, prompting a reschedule of the critical court hearing to November 23.

Tamawood Limited reports a modest profit increase for FY25 alongside the retirement of long-serving Chairman Robert Lynch. Early FY26 sales surge 39%, but a Work in Progress audit prompts a trading blackout.

The Foreign Investment Review Board has extended its deadline for approving Mayne Pharma's acquisition by Cosette Pharmaceuticals, maintaining the current transaction timetable for now.

Mayne Pharma’s acquisition by Cosette Pharmaceuticals faces a regulatory delay as the Foreign Investment Review Board extends its approval deadline, pushing the court hearing to mid-November.